Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900731 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,598
- Enrollment target
NCT00900731 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,598 participants.
The verdict
NCT00900731, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,598 participants
- Enrollment target
Study Summary
This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.
Interventions
- DRUG Placebo to indacaterol
- DRUG Indacaterol 150 μg
- DRUG Tiotropium 18 μg
- DRUG Placebo to tiotropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,598 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00900731
The ClinicalTrials.gov registry entry for NCT00900731 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,598 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo to indacaterol is the first listed.
NCT00900731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00900731 about?
NCT00900731 is a clinical study titled "A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)". This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.
What is the current status of trial NCT00900731?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,598 participants. The study started on 2009-06. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00900731?
The interventions under investigation include: Placebo to indacaterol (DRUG), Indacaterol 150 μg (DRUG), Tiotropium 18 μg (DRUG), Placebo to tiotropium (DRUG).
Who is sponsoring clinical trial NCT00900731?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.